Sergi Mas

Mr. Sergi Mas

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Journal of Psychiatry and Neuroscience
Verified
Journal Article
Open access
BGBorja García-Bueno
Borja García-Bueno
PGPatricia Gasso
Patricia Gasso
KMKarina S. MacDowell
Karina S. MacDowell
LCLuis Callado
Luis Callado
SMSergi Mas
Sergi Mas
JLJuan C. Leza
Juan C. Leza
Background: Alterations in the innate immune/inflammatory system may underlie the pathophysiology of schizophrenia, but we do not understand the mechanisms involved. The main agents of innate immunity are the Toll-like receptors (TLRs), which detect molecular patterns associated with damage and pathogens. The TLR first reported was TLR4, and it is still the most studied one. Methods: We aimed to describe putative modifications to the TLR4 proinflammatory pathway using 2 different strategies in 2 cohorts of patients with schizophrenia and matched controls: 1) quantification of protein and mRNA expression in postmortem prefrontal cortex samples from 30 patients with schizophrenia and 30 controls, and 2) identification of single nucleotide polymorphisms associated with the risk of schizophrenia using whole blood samples from 214 patients with schizophrenia and 216 controls. Results: We found evidence of alterations in the expression of the initial elements of the TLR4 signalling pathway (TLR4, Myeloid differentiation primary response gene 88 [MyD88] and nuclear factor-κ B [NF-κB]) in the PFC of patients with schizophrenia. These alterations seem to depend on the presence/absence of antipsychotic treatment at death. Moreover, a polymorphism within the MyD88 gene was significantly associated with schizophrenia risk. Limitations: The use of 2 different approaches in 2 different cohorts, the lack of a complementary neuropsychiatric group, the possible confounding effects of antipsychotic treatment and suicide are the main limitations of our study. Conclusion: The evidence from this dual approach suggests there is an altered innate immune response in patients with chronic schizophrenia in which the TLR4 proinflammatory pathway could be affected. Improved understanding of the stimuli and mechanisms responsible for this response could lead to improved schizophrenia treatment and better control of the side effects of current antipsychotics.

1 January 2012 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
PGPatricia Gasso
Patricia Gasso
SMSergi Mas
Sergi Mas
OMOriol Molina
Oriol Molina
MBMiquel Bernardo
Miquel Bernardo
ALAmalia Lafuente
Amalia Lafuente
EPEduard Parellada
Eduard Parellada

28 December 2017 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
NFNatalia Rodriguez Ferret
Natalia Rodriguez Ferret
ALAstrid Morer Liñan
Astrid Morer Liñan
EGE. Azucena González-Navarro
E. Azucena González-Navarro
CSCarles Serra-Pages
Carles Serra-Pages
DBDaniel Boloc
Daniel Boloc
LLLuisa Lázaro
Luisa Lázaro
Although the exact etiology of obsessive-compulsive disorder (OCD) is unknown, there is growing evidence of a role for immune dysregulation in the pathophysiology of the disease, especially in the innate immune system including the microglia. To test this hypothesis, we studied inflammatory markers in monocytes from pediatric patients with OCD and from healthy controls. We determined the percentages of total monocytes, CD16+ monocytes, and classical (CD14highCD16−), intermediate (CD14highCD16low), and non-classical (CD14lowCD16high) monocyte subsets in 102 patients with early-onset OCD and in 47 healthy controls. Moreover, proinflammatory cytokine production (GM-CSF, IL-1β, IL-6, IL-8, and TNF-α) was measured by multiplex Luminex analysis in isolated monocyte cultures, in basal conditions, after exposure to lipopolysaccharide (LPS) to stimulate immune response or after exposure to LPS and the immunosuppressant dexamethasone. OCD patients had significantly higher percentages of total monocytes and CD16+ monocytes than healthy controls, mainly due to an increase in the intermediate subset but also in the non-classical monocytes. Monocytes from OCD patients released higher amounts of GM-CSF, IL-1β, IL-6, IL-8, and TNF-α than healthy controls after exposure to LPS. However, there were no significant differences in basal cytokine production or the sensitivity of monocytes to dexamethasone treatment between both groups. Based on monocyte subset distribution and cytokine production after LPS stimulation, patients receiving psychoactive medications seem to have an intermediate inflammatory profile, that is, lower than non-medicated OCD individuals and higher than healthy controls. These results strongly support the involvement of an enhanced proinflammatory innate immune response in the etiopathogenesis of early-onset OCD.

25 March 2014 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PGPatricia Gasso
Patricia Gasso
NFNatalia Rodriguez Ferret
Natalia Rodriguez Ferret
SMSergi Mas
Sergi Mas
MTMireia Pagerols Teixidó
Mireia Pagerols Teixidó
ABA Blázquez
A Blázquez
ALA Lafuente
A Lafuente

1 November 2015 in Journal of Affective Disorders
Verified
Journal Article
Closed access
PGPatricia Gasso
Patricia Gasso
AOAna E Ortiz
Ana E Ortiz
SMSergi Mas
Sergi Mas
ALAstrid Morer Liñan
Astrid Morer Liñan
ACAnna Calvo
Anna Calvo
LLLuisa Lázaro
Luisa Lázaro

1 September 2011 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
SMSergi Mas
Sergi Mas
PGPatricia Gasso
Patricia Gasso
SÁSantiago Álvarez
Santiago Álvarez
JOJacint Ortiz
Jacint Ortiz
JSJose M. Sotoca
Jose M. Sotoca
ALAmalia Lafuente
Amalia Lafuente
Dry cough is the most common reason for stopping angiotensin-converting enzyme inhibitors (ACEi) therapy. The role of ACE in the metabolism of bradykinin has been proposed as a pathogenic mechanism. This study included a complete analysis of the variability of the genes involved in bradykinin metabolism (ACE and XPNPEP2) and bradykinin receptors (BDKRB2). We included two polymorphisms in the ABO (related to ACE levels); two polymorphisms in the AGTR1, and one polymorphism in the BKRB1 (related to ACEi response). A total of 281 patients who had been treated with ACEi were retrospectively recruited [102 patients were considered as cases (cough) and 179 patients were considered as controls (no cough)], and 56 polymorphisms were tested for association. We found that genetic polymorphisms in BDKRB2 [rs8016905; P=0.003; odds ratio (OR)=2.21] and ABO (rs495828; P=0.001; OR=2.45) are associated with ACEi-induced cough after correction for multiple testing. The effect of polymorphisms in ABO was sex specific (female patients; P=0.0006; OR=3.26). When we analyzed the subgroup of patients homozygous GG for rs4343, two polymorphisms in the ACE were found to have protective properties (rs4459610 and rs4267385; P=0.005 and 0.004; OR=0.25). We also found a strong interaction between the ABO polymorphisms, rs495828 and rs8176746 (P<0.0001; OR=3.7). These results highlight the importance of genetic determinants of ACE levels as good predictors of the ACEi response, and provide ABO as a good candidate gene for pharmacogenetic studies of ACEi-related cough. Moreover, our results also confirm the importance of bradykinin in the pathogenesis of this adverse effect.